Light Mode
$2.25 ↑ +0.00 (+0.00%) Trading Up from the previous close of $2.25, $0.01 below the day’s high of $2.26
-0.14 (-5.86%) / 6M
Momentum, market sentiment, and recent alerts
ALEC reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +50.0%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. It develops portfolio of innate immune system programs, designed to functionally repair genetic mutations and enable the rejuvenated immune cells to counteract emerging brain pathologies. Its treatment targets immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders. The company was founded by Asa Abeliovich, Errik B. Anderson, Tillman U. Gerngross, and Arnon Rosenthal in May 2013 and is headquartered in South San Francisco, CA.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.